BASIC RESEARCH
Identification of differentially expressed profiles of lncRNAs and mRNAs in ER-negative and HER-2 positive breast cancer
Submission date: 2017-03-14
Final revision date: 2017-05-17
Acceptance date: 2017-05-18
Publication date: 2017-11-21
Arch Med Sci Civil Dis 2017;2(1):148-160
KEYWORDS
TOPICS
ABSTRACT
Introduction: Breast cancer is one of the most common malignant tumors in the United States. However, the molecular mechanism involved in the progression of breast cancer has remained unclear. Long non-coding RNAs (lncRNA) have been reported as key regulators in the progression and metastasis of cancer.
Material and methods: In this study, we identified significantly differentially expressed mRNAs and lncRNAs in breast cancer using the GSE70947 dataset. Gene ontology (GO) and KEGG pathway was used to explore the key roles of differentially expressed lncRNAs in breast cancer. The dysregulated lncRNAs and mRNAs expression profiles in HER2-positive and ER-negative breast cancer were also analyzed in this study.
Results: Our results showed that PVT1, LOC145837, FLJ40504 and FLJ45983 were significantly decreased in HER2-positive and ER-negative breast cancers. We also constructed the PVT1, LOC145837, FLJ40504 and FLJ45983 mediated cRNA networks in HER2-positive and ER-negative breast cancers. Moreover, using the Betastasis dataset, we found that high PVT1 expression levels were associated with a lower survival rate in breast cancer patients.
Conclusions: These results elucidate the functions of lncRNAs and provide useful information for exploring therapeutic candidate targets and new molecular biomarkers for ER-negative and HER-2 enriched subtype breast cancer.
Material and methods: In this study, we identified significantly differentially expressed mRNAs and lncRNAs in breast cancer using the GSE70947 dataset. Gene ontology (GO) and KEGG pathway was used to explore the key roles of differentially expressed lncRNAs in breast cancer. The dysregulated lncRNAs and mRNAs expression profiles in HER2-positive and ER-negative breast cancer were also analyzed in this study.
Results: Our results showed that PVT1, LOC145837, FLJ40504 and FLJ45983 were significantly decreased in HER2-positive and ER-negative breast cancers. We also constructed the PVT1, LOC145837, FLJ40504 and FLJ45983 mediated cRNA networks in HER2-positive and ER-negative breast cancers. Moreover, using the Betastasis dataset, we found that high PVT1 expression levels were associated with a lower survival rate in breast cancer patients.
Conclusions: These results elucidate the functions of lncRNAs and provide useful information for exploring therapeutic candidate targets and new molecular biomarkers for ER-negative and HER-2 enriched subtype breast cancer.
REFERENCES (30)
1.
Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006; 127: 679-95.
2.
Lin A, Li C, Xing Z, et al. The LINK-A lncRNA activates normoxic HIF1alpha signalling in triple-negative breast cancer. Nat Cell Biol 2016; 18: 213-24.
3.
Prat A, Parker JS, Karginova O, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010; 12: R68.
4.
Osborne CK. Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 1998; 51: 227-38.
5.
Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10869-74.
6.
Finnegan TJ, Carey LA. Gene-expression analysis and the basal-like breast cancer subtype. Future Oncol 2007; 3: 55-63.
7.
Mitri Z, Constantine T, O’Regan R. The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy. Chemother Res Pract 2012; 2012: 743193.
8.
Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003; 100: 8418-23.
9.
Chien AJ, Rugo HS. Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat 2013; 137: 1-12.
10.
Amorim M, Salta S, Henrique R, Jerónimo C. Decoding the usefulness of non-coding RNAs as breast cancer markers. J Transl Med 2016; 14: 265.
11.
Wan X, Huang W, Yang S, et al. Identification of androgen-responsive lncRNAs as diagnostic and prognostic markers for prostate cancer. Oncotarget 2016; 7: 60503-18.
12.
Kim T, Cui R, Jeon YJ, Fadda P, Alder H, Croce CM. MYC-repressed long noncoding RNAs antagonize MYC-induced cell proliferation and cell cycle progression. Oncotarget 2015; 6: 18780-9.
13.
Geisler S, Coller J. RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. Nat Rev Mol Cell Biol 2013; 14: 699-712.
14.
Huang NS, Chi YY, Xue JY, et al. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 (MALAT1) interacts with estrogen receptor and predicted poor survival in breast cancer. Oncotarget 2016; 7: 37957-65.
15.
Niknafs YS, Han S, Ma T, et al. The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. Nat Commun 2016; 7: 12791.
16.
Zhang X, Sun S, Pu JK, et al. Long non-coding RNA expression profiles predict clinical phenotypes in glioma. Neurobiol Dis 2012; 48: 1-8.
17.
Franceschini A, Szklarczyk D, Frankild S, et al. STRING v9.1: Protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res 41 (D1):.
18.
Saito R, Smoot ME, Ono K, et al. A travel guide to Cytoscape plugins. Nat Methods 2012; 9: 1069-76.
19.
Adamcsek B, Palla G, Farkas IJ, Derényi I, Vicsek T. CFinder: Locating cliques and overlapping modules in biological networks. Bioinformatics 2006; 22: 1021-3.
20.
Guttman M, Rinn JL. Modular regulatory principles of large non-coding RNAs. Nature 2012; 482: 339-46.
21.
Shen X, Xie B, Ma Z, et al. Identification of novel long non-coding RNAs in triple-negative breast cancer. Oncotarget 2015; 6: 21730-9.
22.
Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20.
23.
Guan Y, Kuo WL, Stilwell JL, et al. Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clin Cancer Res 2007; 13: 5745-55.
24.
Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin 2012; 65: 10-29.
25.
Wang X, Sehgal L, Jain N, Khashab T, Mathur R, Samaniego F. LncRNA MALAT1 promotes development of mantle cell lymphoma by associating with EZH2. J Transl Med 2016; 14: 346.
26.
Narayanan R, Dalton JT. Androgen receptor: a complex therapeutic target for breast cancer. Cancers (Basel) 2016; 8: 108.
27.
Kümler I, Knoop AS, Jessing CAR, Ejlertsen B, Nielsen DL. Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant. ESMO Open 2016; 1: e000062.
28.
Lousberg L, Collignon J, Jerusalem G. Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies. Ther Adv Med Oncol 2016; 8: 429-49.
29.
Kelly CM, Janjigian YY. The genomics and therapeutics of HER2-positive gastric cancer-from trastuzumab and beyond. J Gastrointest Oncol 2016; 7: 750-62.
30.
Liu FT, Xue QZ, Zhu ZM, et al. Long noncoding RNA PVT1, a novel promising biomarker to predict lymph node metastasis and prognosis: a meta-analysis. Panminerva Med 2016; 58: 160-6.
Share
RELATED ARTICLE
| ISSN: | 2451-0637 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
